Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKBA
  • CUSIP:
Key Metrics:
  • Previous Close: $8.09
  • 50 Day Moving Average: $8.46
  • 200 Day Moving Average: $8.46
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.00
  • P/E Growth: 0.00
  • Market Cap: $148.41M
  • Outstanding Shares: 18,300,000
  • Beta: 0.78
Additional Links:
Companies Related to Akebia Therapeutics:

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $16.43 (102.57% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetDetails
8/23/2016HC WainwrightReiterated RatingBuyView Rating Details
8/11/2016JMP SecuritiesReiterated RatingMarket Perform$16.00View Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingHold$8.00View Rating Details
5/8/2016Brean CapitalReiterated RatingBuyView Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyView Rating Details
3/16/2016Needham & Company LLCLower Price TargetBuy$18.00 -> $14.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00View Rating Details
5/12/2015NomuraReiterated RatingBuy$37.00 -> $27.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016($0.57)($0.95)ViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014($0.34)($0.39)ViewN/AView Earnings Details
5/12/2014($0.38)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-4.13 EPS
Next Year EPS Consensus Estimate: $-4.06 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
DateHeadline
live-pr.com logoNew Market Research Report: Akebia Therapeutics, Inc. (AKBA) - Financial and Strategic SWOT Analysis Review (NASDAQ:AKBA)
www.live-pr.com - August 26 at 3:24 PM
investornewswire.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - August 22 at 3:27 PM
4-traders.com logoAkebia Therapeutics : Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA)
www.4-traders.com - August 22 at 8:12 AM
finance.yahoo.com logo7:04 am Akebia Therapeutics announces the publication of an analysis indicating persistently greater mortality in dialysis-dependent chronic kidney disease patients with agent hyporesponse (NASDAQ:AKBA)
finance.yahoo.com - August 22 at 8:12 AM
publicnow.com logoAkebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA)
www.publicnow.com - August 22 at 8:12 AM
finance.yahoo.com logoAKEBIA THERAPEUTICS, INC. Financials (NASDAQ:AKBA)
finance.yahoo.com - August 17 at 3:26 PM
realistinvestor.com logoAnalysts See Akebia Therapeutics, Inc. (NASDAQ:AKBA) Reporting EPS Of $-1.25 - RealistInvestor.com (NASDAQ:AKBA)
www.realistinvestor.com - August 16 at 3:25 PM
investornewswire.com logoWill Akebia Therapeutics, Inc. (NASDAQ:AKBA) Hit $26 Price Target? - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - August 15 at 3:27 PM
insidermonkey.com logoCalculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals (NASDAQ:AKBA)
www.insidermonkey.com - August 12 at 3:36 PM
finance.yahoo.com logoWhy Akebia Therapeutics (AKBA) Could Be Positioned for a Slump (NASDAQ:AKBA)
finance.yahoo.com - August 12 at 11:58 AM
marketexclusive.com logoCalculating The Impact Of Akebia Therapeutics Inc (NASDAQ:AKBA)’s Pivotals (NASDAQ:AKBA)
marketexclusive.com - August 11 at 3:26 PM
News IconNoteworthy Tuesday Option Activity: AKBA, LGF, D (NASDAQ:AKBA)
www.stockoptionschannel.com - August 9 at 4:28 PM
News IconAkebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA)
ih.advfn.com - August 9 at 4:28 PM
benzinga.com logoBrean Sees Huge Upside In Akebia Shares (NASDAQ:AKBA)
www.benzinga.com - August 9 at 4:28 PM
4-traders.com logoAkebia Therapeutics : reports 2Q loss (NASDAQ:AKBA)
www.4-traders.com - August 9 at 4:28 PM
News IconAkebia Announces Second Quarter 2016 Financial Results (NASDAQ:AKBA)
www.biospace.com - August 9 at 4:28 PM
finance.yahoo.com logoAkebia's Market Potential Undervalued By The Street, Says JMP (NASDAQ:AKBA)
finance.yahoo.com - August 9 at 4:28 PM
seekingalpha.com logoAkebia misses by $0.38 - Seeking Alpha (NASDAQ:AKBA)
seekingalpha.com - August 8 at 8:52 PM
sg.finance.yahoo.com logoAkebia Therapeutics reports 2Q loss (NASDAQ:AKBA)
sg.finance.yahoo.com - August 8 at 8:52 PM
businesswire.com logoAkebia Therapeutics Appoints Scott A. Canute to its Board of Directors - Business Wire (press release) (NASDAQ:AKBA)
www.businesswire.com - August 2 at 9:01 PM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fi (NASDAQ:AKBA)
biz.yahoo.com - August 2 at 9:01 PM
publicnow.com logoAkebia Therapeutics Appoints Scott A. Canute to its Board of Directors (NASDAQ:AKBA)
www.publicnow.com - August 2 at 9:01 PM
biz.yahoo.com logoAKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:AKBA)
biz.yahoo.com - July 28 at 4:07 PM
equities.com logoAkebia Therapeutics Inc. (AKBA) Jumps 5.4% on July 27 - Equities.com (NASDAQ:AKBA)
www.equities.com - July 28 at 12:03 PM
ftsenews.co.uk logoNew Broker Ratings For Akebia Therapeutics, Inc. (AKBA) - FTSE News (NASDAQ:AKBA)
www.ftsenews.co.uk - July 25 at 8:11 AM
News IconEquity Roundup: Stock Performance Focus on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph (NASDAQ:AKBA)
presstelegraph.com - July 23 at 3:24 PM
News IconAkebia Therapeutics, Inc. (NASDAQ:AKBA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 21 at 3:24 PM
kcregister.com logoWhy Need to Watch: Invuity (NASDAQ:IVTY), Akebia Therapeutics (NASDAQ:AKBA), Taiwan Semiconductor ... - KC Register (NASDAQ:AKBA)
www.kcregister.com - July 20 at 11:32 AM
News IconAkebia Therapeutics Incorporated (NASDAQ:AKBA) Short Interest Increased By 0.41% - Consumer Eagle (NASDAQ:AKBA)
www.consumereagle.com - July 19 at 3:25 PM
investornewswire.com logoIs $26 Price Target Attainable For Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - July 18 at 3:27 PM
News IconShares Moving Down on the Week: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 17 at 8:10 AM
News IconAre Analysts Bullish Akebia Therapeutics Inc (NASDAQ:AKBA) After Last Week? - Consumer Eagle (NASDAQ:AKBA)
www.consumereagle.com - July 16 at 11:49 AM
equities.com logoAkebia Therapeutics Inc. (AKBA) is Trading Lower on Unusual Volume for July 13 - Equities.com (NASDAQ:AKBA)
www.equities.com - July 16 at 11:49 AM
news.cmlviz.com logoOption Market: Akebia Therapeutics Inc Risk Hits An Elevated Level - CML News (NASDAQ:AKBA)
news.cmlviz.com - July 14 at 3:26 PM
News IconAkebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 13 at 3:26 PM
kcregister.com logoActive Watch List: Akebia Therapeutics, Inc. (NASDAQ:AKBA), Cisco Systems, Inc. (NASDAQ:CSCO), IberiaBank Corp ... - KC Register (NASDAQ:AKBA)
www.kcregister.com - July 12 at 3:28 PM
investornewswire.com logoStrong Sell Calls For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 0 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - July 11 at 3:25 PM
News IconAkebia Therapeutics Incorporated (NASDAQ:AKBA) Sellers Covered 4.1% of Their Shorts - Press Telegraph (NASDAQ:AKBA)
presstelegraph.com - July 9 at 11:31 AM
News IconAkebia Therapeutics Inc Formed a Bearish Double Bottom Pattern, Could Be One of The Worst Performers Going ... - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 8 at 8:36 PM
news.cmlviz.com logoAkebia Therapeutics, Inc. Stock Momentum at Critical Inflection Point - CML News (NASDAQ:AKBA)
news.cmlviz.com - July 8 at 11:28 AM
News IconStock Tracking Down This Month; Investor Alert on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 7 at 11:20 AM
News IconCan Akebia Therapeutics, Inc. (NASDAQ:AKBA) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 7 at 11:20 AM
equities.com logoAkebia Therapeutics Inc. (AKBA) Jumps 6.13% on July 06 - Equities.com (NASDAQ:AKBA)
www.equities.com - July 7 at 11:20 AM
News IconIncreased Volatility Watch for: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - July 6 at 3:25 PM
publicnow.com logoAkebia to Present at the Cantor Fitzgerald Annual Healthcare Conference (NASDAQ:AKBA)
www.publicnow.com - July 5 at 4:11 PM
investornewswire.com logoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Expected to Reach Highs Of $26 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - July 4 at 3:24 PM
fiscalstandard.com logoBroker Outlook For The Week Ahead Akebia Therapeutics, Inc. (AKBA) - Fiscal Standard (NASDAQ:AKBA)
www.fiscalstandard.com - July 4 at 8:12 AM
News IconAkebia Therapeutics Inc on Focus After Raising In Today's Session - Engelwood Daily (NASDAQ:AKBA)
www.engelwooddaily.com - June 29 at 3:23 PM
News IconCovering the Bases on Akebia Therapeutics, Inc. (NASDAQ:AKBA): Where is the Stock Going? - Press Telegraph (NASDAQ:AKBA)
presstelegraph.com - June 28 at 8:35 AM
investornewswire.com logoStrong Sell Calls Recommendations For Akebia Therapeutics, Inc. (NASDAQ:AKBA) At 0 - Investor Newswire (NASDAQ:AKBA)
www.investornewswire.com - June 28 at 8:35 AM

Social

Akebia Therapeutics (NASDAQ:AKBA) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff